




RealRate

PHARMACEUTICAL 2020

CHINOOK THERAPEUTICS INC. Rank 237 of 358





RealRate

PHARMACEUTICAL 2020

CHINOOK THERAPEUTICS INC. Rank 237 of 358



The relative strengths and weaknesses of CHINOOK THERAPEUTICS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of CHINOOK THERAPEUTICS INC. compared to the market average is the variable Expenses, increasing the Economic Capital Ratio by 34% points. The greatest weakness of CHINOOK THERAPEUTICS INC. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 179% points.

The company's Economic Capital Ratio, given in the ranking table, is 12%, being 25% points below the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	217,902
Cost of Goods Sold	0
Intangible Assets	27,145
Liabilities, Current	21,601
Liabilities, Non-Current	199,539
Other Assets	21,578
Other Compr. Net Income	-526
Other Expenses	3,148
Other Liabilities	4,578
Other Net Income	5,358
Other Revenues	17,258
Property and Equipment	24,688
Research and Development	67,045
Selling, General and Administrative Expense	34,795

Output Variable	Value in 1000 USD
Assets	291,313
Liabilities	225,718
Expenses	104,988
Revenues	17,258
Stockholders Equity	65,595
Net Income	-82,372
Comprehensive Net Income	-82,635
Economic Capital Ratio	12%